Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06109181 · ClinicalTrials.gov registry record · Phase 1
Gene Therapy for ACM Due to a PKP2 Pathogenic Variant
A Phase 1 study of Arrhythmogenic Cardiomyopathy and PKP2-ACM, sponsored by Lexeo Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 5
- Study locations
NCT06109181: Active Phase 1 study of Arrhythmogenic Cardiomyopathy and PKP2-ACM, sponsored by Lexeo Therapeutics.
NCT06109181 is a Phase 1 study of Arrhythmogenic Cardiomyopathy and PKP2-ACM that is active but no longer recruiting, run by Lexeo Therapeutics. The registered enrollment target is 10 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06109181, a Phase 1 study of Arrhythmogenic Cardiomyopathy and PKP2-ACM, is active but no longer recruiting, sponsored by Lexeo Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a Phase 1/2, first-in-human, open-label, intravenous, dose-escalating, multicenter trial that is designed to assess the safety and tolerability of LX2020 in adult patients with PKP2-ACM
Primary Outcome
Evaluation of Safety and Tolerability of LX2020
Conditions Studied
Interventions
- GENETIC LX2020
Study Locations (5)
California
- Stanford University - Stanford
Maryland
- Johns Hopkins University - Baltimore
Michigan
- University of Michigan - Ann Arbor
New York
- University of Rochester - Rochester
South Carolina
- Medical University of South Carolina - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2024-02-29 |
| Est. Completion | 2027-03 |
| Phase | Phase 1 |
What the registry record for NCT06109181 still lists
NCT06109181 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower).
The record links to 3 conditions, with Arrhythmogenic Cardiomyopathy appearing as the primary indexed condition, and to 1 intervention - of which LX2020 is the first listed.
NCT06109181 lists 5 locations in 5 states (California, Maryland, Michigan).
Frequently Asked Questions
What is clinical trial NCT06109181 about?
NCT06109181 is a clinical study titled "Gene Therapy for ACM Due to a PKP2 Pathogenic Variant". This is a Phase 1/2, first-in-human, open-label, intravenous, dose-escalating, multicenter trial that is designed to assess the safety and tolerability of LX2020 in adult patients with PKP2-ACM
What is the current status of trial NCT06109181?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2024-02-29. Estimated completion is 2027-03.
What conditions does trial NCT06109181 study?
This clinical trial studies the following conditions: Arrhythmogenic Cardiomyopathy, PKP2-ACM, PKP2-ARVC.
What interventions are being tested in trial NCT06109181?
The interventions under investigation include: LX2020 (GENETIC).
Who is sponsoring clinical trial NCT06109181?
This trial is sponsored by Lexeo Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06109181 being conducted?
This trial has 5 study locations across California, Maryland, Michigan, New York, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Arrhythmogenic Cardiomyopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06109181's enrollment target sits among peer trials
10 1913th of 2000 higher than 46 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI